key: cord-0838056-s3hx56xd
authors: Kollias, Anastasios; Kyriakoulis, Konstantinos G.; Syrigos, Nikolaos K.; Stergiou, George S.
title: Anticoagulation therapy in COVID-19: Is there a dose-dependent benefit?
date: 2020-12-29
journal: Thromb Res
DOI: 10.1016/j.thromres.2020.12.013
sha: 8ceb1016a3feba0ee5fdbb17275f8d9782707a34
doc_id: 838056
cord_uid: s3hx56xd

nan

We read with interest the study by Lynn et al. among 402 hospitalized COVID-19 patients, which did not show any survival benefit in those who were administered therapeutic dosage of anticoagulation (AC) compared to standard thromboprophylaxis [1] . It should be mentioned that the study had retrospective design and therapeutic AC was empirically prescribed mainly to patients with severe COVID-19, especially those admitted to Intensive Care Unit (ICU) [1] . Another retrospective study including 4389 COVID-19 patients, showed that the administration of prophylactic or therapeutic AC therapy was associated with lower in-hospital mortality and intubation compared with no AC; however, in a sub-analysis including patients initiating AC ≤48 h from admission, no significant difference was observed between therapeutic and prophylactic AC, despite a trend in favor of the former [2] . Interestingly, a retrospective study in 468 hospitalized COVID-19 patients showed that initial administration of intermediate dose of AC (high-intensity thromboprophylaxis) was associated with lower mortality rate compared to standard prophylactic AC, whereas mortality was higher in the group receiving therapeutic AC therapy [3] . It should be mentioned that in the latter study, the choice of the AC dosage was based upon institutional algorithms and at the discretion of the admitting provider [3] . Other studies with more restricted sample sizes have also shown a trend for better outcomes with implementation of more aggressive thromboprophylaxis protocols [4, 5] .

These findings are highly interesting regarding the optimal AC dosage in COVID-19 patients. However, it should be mentioned that in these studies, therapeutic AC was administered empirically or according to protocols taking into consideration adverse parameters related to COVID-19 severity, which in turn might have predicted an unfavorable prognosis. Therefore, the benefit of the therapeutic AC might have been blunted by the severity of COVID-19 in these high-risk patients despite the fact that the authors used a meticulous statistical approach and adjusted for several confounding factors [1] [2] [3] .

On the other hand, a recent study in 152 critically ill COVID-19 patients admitted to ICU, showed that high-dose AC was associated with lower cumulative incidence of thromboembolic events and fewer deaths compared to lower AC dosage [6] . Further to the retrospective design of the study, two important methodological issues should be considered: (i) all patients had severe disease requiring admission to ICU, and (ii) the selection of the AC dosage was based on local standardized recommendations, independent of the disease severity or risk of thrombosis, and these recommendations were modified over time introducing a 'time-related randomization' pattern. Indeed, the 3 AC dosing groups (low, medium, high) did not differ in terms of patients' anthropometric characteristics, comorbidities, and Simplified Acute Physiology Score III [6] . A similar study (retrospective design, ICU patients, selection of AC dosage based on local recommendations which were modified over time) showed that increased (intermediate or therapeutic) compared to standard prophylactic AC dosage resulted in a decrease in the prevalence of femoral/popliteal deep vein thrombosis [7] . Thus, the findings of the latter studies seem to be in favor of higher AC dosages in patients with severe COVID-19.

Apart from issues regarding the efficacy of the AC treatment, the safety profile of such interventions should be carefully considered. Interestingly, among the abovementioned studies, only in the study by Lynn et al., therapeutic dosage of AC was associated with increased risk of clinically significant bleeding events compared to lower AC dosages [1] . However, in this study therapeutic AC was more likely to be administered to frail patients with severe COVID-19 which could imply an indication bias.

At present, retrospective observational studies constitute the sole source of evidence regarding the optimal AC dosing in COVID-19 patients. Evidence shows that higher AC dosages are administered in COVID-19 patients with critical disease and especially those in ICU based on local protocols and recommendations. However, studies seem to be controversial as to whether these higher AC doses provide additional benefit compared to standard thromboprophylaxis. The beneficial effect of different AC doses should be examined taking into consideration the heterogeneity in the severity of COVID-19. Randomized controlled trials are the most appropriate for the definition of the optimal AC dose in different patient categories and are currently lacking. Official recommendations suggest prophylactic AC therapy, yet intermediate intensity AC should be considered in high-risk patients. However, this treatment strategy is mainly based on observational studies and expert opinion and not on high-quality evidence [8, 9] . 

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

The effect of anticoagulation on clinical outcomes in novel Coronavirus (COVID-19) pneumonia in a

Anticoagulation, bleeding, mortality, and pathology in hospitalized patients with COVID-19

Intensity of anticoagulation and survival in patients hospitalized with COVID-19 pneumonia

COVID-19 associated coagulopathy: thrombosis, hemorrhage and mortality rates with an escalated-dose thromboprophylaxis strategy

Impact of implementation of an individualised thromboprophylaxis protocol in critically ill ICU patients with COVID-19: a longitudinal controlled before-after study

Dosing of thromboprophylaxis and mortality in critically ill COVID-19 patients

Increased anticoagulation reduces proximal deep vein thrombosis in mechanically ventilated COVID-19 patients

Subcommittee on Perioperative, Critical Care Thrombosis, Haemostasis of the Scientific, Standardization Committee of the International Society on Thrombosis and Haemostasis. Scientific and Standardization Committee communication: clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19

Guidance for the management of patients with vascular disease or cardiovascular risk factors and COVID-19: position paper from VAS-European Independent Foundation in Angiology/Vascular Medicine